Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer [NEOMUN]
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NEOMUN
- 02 Jul 2018 Status changed from not yet recruiting to recruiting.
- 02 Jul 2018 Planned End Date changed from 1 Jan 2022 to 1 Feb 2022.
- 02 Jul 2018 Planned primary completion date changed from 1 Jan 2020 to 1 Feb 2020.